| Literature DB >> 26060625 |
Fatemeh Sadat Hoseini1, Mohammad Eslami2, Mohammed Abbasi3, Fatemeh Noroozi Fashkhami3, Soheila Besharati3.
Abstract
BACKGROUND: We aimed to compare acceptability of Levonorgestrel with the Yuzpe regimen among Iranian women based on their side-effects and resulting changes in the amount and pattern of menses.Entities:
Keywords: Emergency contraception; Levonorgestrel; Side-effects; Yuzpe regimen
Year: 2013 PMID: 26060625 PMCID: PMC4436545
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Baseline characteristics of eligible participants
| Variable | Mean (SD) in HD group | Mean (SD) in LNG group | Mean (SD) total | ||
|---|---|---|---|---|---|
| Age | 28.8 (6.2) | 28.8 (5.6) | 28.8 (5.9) | 0.874 | |
| Weight | 66.7 (12.1) | 67.4 (11.4) | 67.0 (11.7) | 0.493 | |
| Height | 159.4 (5.8) | 160.0 (5.5) | 159.6 (5.7) | 0.257 | |
| BMI | 26.3 (4.6) | 26.3 (4.2) | 26.3 (4.4) | 0.893 | |
| Number of pregnancies | 1.8 (1.1) | 1.7 (1.1) | 1.8 (1.1) | 0.484 | |
| Number of childbirth | 1.5 (0.7) | 1.4 (0.8) | 1.5 (0.8) | 0.862 | |
| Number of abortions | 0.3 (0.7) | 0.3 (0.6) | 0.3 (0.6) | 0.252 | |
| Frequency (percentage) of prior contraceptive method | Condom | 142 (54%) | 167 (48.8%) | 269 (51.4%) | 0.239 |
| Conventional | 121 (46%) | 133 (51.2%) | 254 (48.6%) | ||
Knowledge and prior experience of emergency contraception among participants in both treatment groups
| Variable | Status | Frequency (Percentage) in HD group | Frequency (Percentage) in LNG group | Frequency (Percentage) total | |
|---|---|---|---|---|---|
| Knowledge of ECPs | Perfect knowledge | 21 (8) | 22 (8.6) | 43 (8.3) | - |
| Know HD and LD pills | 122 (46.4) | 118 (46.3) | 240 (46.3) | ||
| Do not know number of pills | 4 (1.5) | 5 (2) | 9 (1.7) | ||
| Know the access method | 48 (18.3) | 60 (23.5) | 108 (20.8) | ||
| Do not know ECPs | 68 (25.9) | 50 (20) | 118 (22.8) | ||
| Prior use of | Yes | 89 (33.6) | 176 (32.4) | 174 (66.7) | 0.78 |
| ECPs | No | 85 (66.4) | 177 (67.6) | 353 (32.9) | |
| Status of prior ECPs use | Correct | 77 (83.7) | 68 (78.2) | 145 (81) | 0.573 |
| Incorrect | 11 (12) | 15 (17.2) | 26 (4.5) | ||
| Do not remember | 4 (4.3) | 4 (4.6) | 8 (14.5) |
Status of drug administration among participants
| Variable | Status | Frequency (Percentage) in HD group | Frequency (Percentage) in LNG group | Frequency (Percentage) total | |
|---|---|---|---|---|---|
| Time interval between coitus and drug administration | < 12 h | 177 (66.5) | 173 (66) | 350 (66.3) | 0.961 |
| 12-24 h | 31 (11.7) | 30 (11.5) | 61 (11.6) | ||
| 24-48 h | 45 (16.9) | 48 (18.3) | 93 (17.6) | ||
| 48-72 h | 13 (4.9) | 11 (4.2) | 24 (4.5) | ||
| Time interval between doses | < 12 h | 241 (90.6) | 237 (90.1) | 487 (90.4) | 0.059 |
| 12-24 h | 18 (6.8) | 25 (9.5) | 43 (8.1) | ||
| Did not take | 7 (2.6) | 1 (0.4) | 8 (1.5) | ||
| Status of ECP use | Correct | 186 (69.9) | 161 (61.2) | 347 (65.6) | 0.035 |
| Incorrect | 80 (30.1) | 102 (38.8) | 182 (34.4) | ||
| week of drug administration | Yes | 86 (32.6) | 123 (46.9) | 209 (39.7) | 0.001 |
| No | 178 (67.4) | 139 (53.1) | 317 (60.3) |
Frequency of side effects within one week of drug administration
| Side effects | Frequency (Percentage) in HD group | Frequency (Percentage) in LNG group | Frequency (Percentage) total | ||
|---|---|---|---|---|---|
| Vomiting | Severe | 66 (24.8) | 12 (4.6) | 78 (14.7) | < 0.001 |
| Moderate | 99 (37.2) | 52 (19.8) | 151 (28.5) | ||
| Mild | 101 (38) | 199 (75.7) | 300 (56.7) | ||
| Nausea | 73 (24.7) | 9 (3.4) | 82 (15.5) | < 0.001 | |
| Headache | 122 (45.9) | 106 (40.3) | 228 (43.1) | 0.197 | |
| Fatigue | 124 (46.6) | 102 (38.8) | 226 (42.7) | 0.069 | |
| Dizziness | 125 (47) | 98 (37.3) | 223 (42.2) | 0.023 | |
| Breast tenderness | 51 (19.2) | 58 (22.1) | 109 (20.6) | 0.413 | |
| Stomach pain | 106 (39.8) | 105 (39.9) | 211 (39.9) | 0.986 | |
| Nose spot | 56 (21.1) | 61 (23.2) | 117 (22.1) | 0.553 | |
| Diarrhea | 54 (20.3) | 50 (19) | 104 (19.7) | 0.709 | |
Amount of menstrual bleeding before and after drug administration and the resulting changes in menstrual bleeding patterns
| Variable | Mean (SD) in HD group | Mean (SD) in LNG group | Mean (SD) total | |
|---|---|---|---|---|
| Spotting before drug administration | 38.8 (21.9) | 40.3 (21.8) | 39.5 (21.8) | 0.428 |
| Spotting after drug administration | 35.2 (22.8) | 38.7 (25.5) | 36.9 (24.2) | 0.093 |
| Change of spotting pattern | −3.6 (22.1) | −1.5 (25.5) | −2.6 (23.8) | 0.326 |